Clinical trials: Locally Advanced Pancreas Cancer
Pancreatic Cancer
Study of Combined RHUMAB VEGF and Capecitabine-based Chemoradiation for Patients With Locally Advanced Pancreatic Cancer
The goal of this clinical research study is to find the highest safe dose of the drug Bevacizumab that can be given in combination with chemoradiation for the treatment of pancreatic cancer.
- Trial name
- NCT00047710
- Testing
- Bevacizumab, Capecitabine, Radiotherapy
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Pancreatic Cancer
A Dose Escalation Trial of Stereotactic Body Radiotherapy (SBRT) After Induction Chemotherapy for Locally Advanced Pancreatic Cancer
The purpose of this study is to find out the maximum dose of SBRT that can be safely given after chemotherapy for treatment of pancreatic cancer that cannot be removed surgically.
- Trial name
- NCT02643498
- Testing
- Stereotactic Body Radiotherapy (SBRT)
- Where
- 7 sites in United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Memorial Sloan Kettering Cancer Center
Pancreatic Cancer
Prediction of Surgical Resectability After FOLFIRINOX Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: the Role of Diffusion Weighted Magnetic Resonance Imaging, Radiomics and Liquid Biopsy (PeRFormanCe Trial)
In this prospective study, new diagnostic tools will be explored for patients with borderline resectable and locally advanced pancreatic ductal adenocarcinoma (BR or LAPDA) who undergo neoadjuvant chemotherapy with FOLFIRINOX.
- Trial name
- PeRFormanCe (NCT05298722)
- Testing
- Imaging analysis of CT-scan and MRI with radiomics and genetic analysis of peripheral blood samples and questionnaires.
- Where
- 8 sites in Belgium, Netherlands
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- University Hospital, Ghent
Pancreatic Cancer
A Phase II Study of Combine Modality Therapy in Locally Advanced Pancreatic Cancer
Induction chemotherapy will be administered every 2 weeks for 6 cycles (about 3 months). Patients who have radiological evidence of progressive disease will be shifted to salvage chemotherapy.
- Trial name
- NCT00149578
- Testing
- Gemcitabine Oxaliplatin 5FU and Leucovorin
- Where
- 2 sites in Taiwan
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- National Health Research Institutes, Taiwan